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Preemptive ramipril therapy delays renal failure and reduces and typical ocular changes [1, 2]. The disease is caused
renal fibrosis in COL4A3-knockout mice with Alport syndrome. by mutations in type IV collagen genes, which code for
Background. Alport syndrome (AS) is a common hereditary a major constituent of basement membranes. While thecause of end-stage renal failure in adolescence due to defects
1/2 (IV) chains are ubiquitous in basement mem-in type IV collagen genes. Molecular genetics allows early diag-
nosis, however, no preventive strategy can be offered. Using the branes, the 3(IV), 4(IV) and 5(IV) chains show a
COL4A3 / mouse, an animal model for human AS, we restricted distribution and are specifically expressed in
evaluated therapy with ramipril in mice. the glomerulus, inner ear, and eye [3]. Mutations of oneMethods. One hundred and twenty-two Alport-mice were
COL4A3, A4 or A5 gene not only alter or abolish expres-treated with 10 mg/kg/day ramipril added to drinking water.
Proteinuria, serum-urea and lifespan were monitored. Renal sion of the corresponding (IV) chain, but also lead
matrix was characterized by immunohistochemistry, light- and to an abnormal basement membrane with decrease or
electron microscopy, and Western blot. absence of the 3(IV), 4(IV) and 5(IV) chain. HowResults. Untreated COL4A3/ mice died from renal fail-
these COL4-mutations initiate the progressive nephritis,ure after 71  6 days. Early therapy starting at four weeks of
age and continuing to death delayed onset and reduced the renal scarring and subsequent renal failure in AS is not
extent of proteinuria. Uremia was postponed by three weeks well understood [3–6].
in treated animals. Lifespan increased by more than 100% to To date, numerous mutations have been described in150  21 days (P  0.01). In parallel, decreased deposition of
the COL4A3, A4, and A5 genes of Alport-families [7, 8],extracellular matrix and lessened interstitial fibrosis as well as
reduced amounts of renal transforming growth factor-1 allowing early diagnosis in asymptomatic children or even
(TGF-1) could be demonstrated. Late therapy starting at prenatally. However, despite of diagnosis decades before
seven weeks decreased proteinuria, however, lifespan did not end-stage renal failure (ESRF) develops, no therapy canincrease significantly.
be offered to delay or even prevent renal failure.Conclusions. The results indicate an antiproteinuric and anti-
fibrotic nephroprotective effect of ramipril in COL4A3 / While studying about 400 families with AS in Ger-
mice is mediated by down-regulation of TGF-1. This effect in many, Switzerland and Austria, we found evidence that
mice is enhanced by initiation of therapy during pre-symptom- medical treatment with angiotensin-converting enzymeatic disease. The data in COL4A3 / mice as an animal-
(ACE)-inhibitors of children with nephrotic syndromemodel for Alport syndrome suggest that ramipril might as well
delay renal failure in humans with AS. Early diagnosis and due to AS without hypertension may lead to reduction
preemptive treatment also may be crucial in humans. of proteinuria and also possibly delay renal failure. How-
ever, small family numbers, different clinical courses,
different mutations in different type IV collagen genes
Alport syndrome (AS) is a hereditary nephropathy and the 15 to 30 year long course of AS make it necessary
characterized by a family history of hematuria and pro- to have a suitable animal model to evaluate the benefit
teinuria, progressive renal failure, sensorineural deafness of ACE-inhibitors on renal failure in AS.
The aim of the study was to evaluate the effect of the
1 See Editorial by Abbate and Remuzzi, p. 764. ACE-inhibitor ramipril in a suitable animal model for
AS. The COL4A3 knockout mouse was used [9], whoseKey words: hereditary kidney disease, type IV collagen, ACE-inhibi-
tors, extracellular matrix, treatment of renal disease, ramipril. phenotype was found to be very similar to human AS
(abstract; Gross et al, J Am Soc Nephrol 12:A2134, 2000)Received for publication May 27, 2002
[9]. The mouse model shows a very constant phenotype.and in revised form August 7, 2002
Accepted for publication October 1, 2002 In contrast, in humans over 300 diverse mutations are
known in either 3, 4 or 5 chains of type IV collagen, 2003 by the International Society of Nephrology
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and result in differences in the severity of the AS pheno- added to the drinking water, stored at 4C and replaced
type [7, 8]. twice a week. Ramipril remains stable in water for more
The animal model also permits the study of a high than four days at room temperature [10]. Daily fluid
number of “patients” leading to statistically significant intake was measured in animals of different sex and age
data. Thus, clear clinical end points could be obtained for a two-month period. This method ensured that a daily
and evaluated further by immunohistochemistry, light-, dose of 10 mg/kg/day ramipril was applied via drinking
and electron microscopy, and immunoblot analysis of water during the whole experiment. This dosage in mice
renal tissue. Together this allowed us to assess the effect is well below the toxic range and equivalent to the maxi-
of ramipril in this model for human AS. In order to find mum therapeutic dose of 10 mg per day in humans [10].
the optimal beginning and duration of medical therapy,
Animal groupsdifferent therapeutic regimes were evaluated, first with
an early start versus a late start of therapy, and secondly Mice were been bred on a 129/SvJ genetic background
examining long duration versus short duration of therapy. to reduce individual differences. Where possible animals
from the same litter were allotted to different treatment-
groups again to minimize any possible genetic variation.METHODS
Heterozygous and wild-type mice from the same litterGenotyping
were kept in the same cages to serve as controls. A total
Heterozygous COL4A3 knockout mice (Jackson Im- number of 122 homozygous COL4A3 null mice were
munoresearch Laboratories, Westgrove, PA, USA) were divided into four groups for medication:
crossbred. Genotyping was carried out by polymerase
chain reaction (PCR) as described before (abstract; ibid) (I) Untreated animals (N  56);
[9]. PCR was repeated in all homozygous animals to (II) Late therapy, mice with proteinuria 3 g/L,
exclude artifacts. Tail biopsy, DNA extraction and PCR starting at week 7 (N  18);
were repeated in all animals living for more than 12 (III) Early, short therapy starting at the 4th week of
weeks to ensure the genotype. life (before onset of proteinuria) until week 10
(when uremia develops; N  24);Clinical chemistry and proteinuria
(IV) Early, long therapy starting at the 4th week of
All procedures and treatment protocols for the mice
life (before onset of proteinuria) until death
were previously approved by local German authorities
(N  24).(AZ K 17, 7/00) and supervised by veterinarians. Ani-
mals were divided into groups of 4 to 8 mice. Proteinuria Statistics
and serum urea were monitored every other week starting
Data were analyzed by Log Rank statistic (survival anal-at week 4 (Figs. 2 and 3). Urine was sampled by placing
ysis; Fig. 1) and two-way analysis of variance (ANOVA).mice in metabolic cages. Three microliters of urine were
used for microelectrophoresis on a gradient polyacryl- Light and electron microscopy
amide gel, a semiquantitative technique used in human
Mice were transcardially perfused with a solution ofnephrology to qualify (by molecular weight from 10 to
2% paraformaldehyde and 2% glutaraldehyde buffered1000 kD) and quantify proteinuria (Protein Diagnostic
with 0.1 mol/L sodium cacodylate, pH 7.3. Kidneys wereLaboratory, Department of Internal Medicine I, Mer-
immediately removed and immersion-fixed for one toheim Medical Center, Cologne, Germany). The major
three days. For epoxy resin embedding, external renaladvantage of this technique compared to sodium dodecyl
cortex was washed extensively with 0.1 mol/L sodiumsulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
cacodylate and post-fixed in 1% buffered osmium tetrox-of urinary proteins is that only microliters of urine are
ide for four hours. Tissue was dehydrated in gradednecessary for reliable results. The gels were subsequently
ethanol, including a uranylic acetate staining step over-stained by Commassie blue and analyzed by densitome-
night in 70% ethanol. Before infiltration with Aralditetry. Serum urea levels were analyzed in 250 to 1000 	L
Cy 212 epoxy resin (Serva, Heidelberg, Germany), pro-blood from sacrificed animals, placed in heparin-covered
pylene oxide was used as an inter-medium. Tissue blockscapillaries (generally used in human newborns) on a
were cured for 60 hours at 60C. Semithin (500 nm) andHitachi 917 Automatic Analyzer (Boehringer Mann-
thin (60 nm) sections were taken on a Reichert Ultracutheim, Mannheim, Germany). Animals were weighed ev-
UCT ultramicrotome. Glomeruli were identified in semi-ery other week, and lifespan was monitored daily.
thin sections stained with methylene blue and in thin
Medical therapy sections stained with uranyl acetate and lead citrate. A
Zeiss Axiophot microscope (Go¨ttingen, Germany) forFollowing the recommendations of the manufacturer
(Aventis GmbH, Bad Soden, Germany), ramipril was light microscopy and a Zeiss EM 902 microscope for
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electron microscopy were used for histological documen-
tation.
Immunohistochemistry
Six to eight animals per group were sacrificed at weeks
7 and 10, and kidneys for cryosections embedded in
Tissue-Tek (Sakura, Zoeterwoude, The Netherlands),
stored at 80C for subsequent 6 to 7 	m sections on
a Leica Kryotom CM3050 (Bensheim, Germany). For
paraffin-sections, kidneys were fixated in 4% paraform-
aldehyde plus 0.1 mol/L phosphate-buffered saline (PBS)
and vacuum-embedded in a Shandon Citadel1000 (Pitts-
burgh, PA, USA). Paraffin embedded kidneys were sec-
tioned at 4 to 5 	m on a Microm HM355S (Walldorf,
Germany). Sections were washed three times in PBS for
five minutes at room temperature and blocked by incuba-
tion with 5% bovine serum albumin (BSA) in PBS for 30
minutes at room temperature. Sections were incubated
overnight at 4C with the primary antibodies rabbit anti-
Fig. 1. Analysis of lifespan of ramipril-treated animals compared toEHS-laminin (1:1000; gift from M. Paulsson, Cologne,
controls. Lifespan until death from renal failure increased significantlyGermany), and goat anti-fibronectin (1:100; St. Cruz,
by early short treatment (group III) until the 10th week of age from
Heidelberg, Germany). As a negative control, slides were 71  5.8 to 104  13.3 days (P  0.001). When therapy was continued
beyond the 10th week (group IV), animals lived twice as long (150 incubated with control immunoglobulin. The sections
20.7 days; P  0.001) as untreated COL4A3-knockouts. Late therapy
were then washed three times in a solution of PBS and (group II) did not increase lifespan significantly (75  6.5 days).
1.9% NaCl. Subsequently, secondary antibodies labeled
with Cy3 as fluorescent dye (goat anti-rabbit IgG and goat
anti-mouse IgG from Jackson ImmunoReagents) were
RESULTSadded for one hour, followed by the washing procedure
Ramipril extended the lifespan of COL4A3 / micedescribed earlier.
A total number of 552 animals, 22% of them being
Western blot COL4A3 /, were generated within nine-month-old
animals and were from a SvJ/129 background to mini-Aliquots of tissue extracts from two to three kidneys
mize interindividual genetic differences. Life expectancyof different animals (30 	g protein) were dissolved in
was continuously documented during the experimentSDS-sample buffer, separated by electrophoresis in a
(Fig. 1). No animals were lost due to infections or adverseSDS-polyacrylamide gel (12.5%) under reducing condi-
effects of therapy during this trial, and no obvious sidetions, transferred to a nitrocellulose membrane, and
effects were noted. No signs of severe hypertension suchblocked for 60 minutes at room temperature with 5%
as heart-hypertrophy, increased septum size or mediamilk-powder in a 0.2 mol/L Tris-HCl buffer, pH 7.6,
sclerosis were found in any animals.containing 0.1% Tween 20 solution (TBST buffer; Fisher
The lifespan of untreated COL4A3 / mice (group
Scientific, Pittsburgh, PA, USA). Mouse anti-transform-
I) was 71  5.7 days. The life expectancy of mice in
ing growth factor-1 (TGF-1; R&D Systems, Minneap- group II animals (late therapy) did not increase signifi-
olis, MN, USA) as the primary antibody was diluted in cantly [75  6.5 days; confidence interval (CI) 2 until
TBST and then added to the membrane and allowed 
9 days], while the lifespan in group III mice (early
to incubate for 60 minutes at room temperature. The short-term therapy until week 10) increased by almost
membrane was washed three times with TBST and then 50% (104  13 days, P  0.01, 99% CI, 23 to 43 days;
incubated for 60 minutes with secondary antibody conju- Fig. 1). Mice in group IV (starting therapy early and
gated with HRP (Dako, Hamburg, Germany). The mem- continued until death) showed an even better response
brane was washed as above, and the blot was developed with their lifespan more than doubled to 150  21 days
using chemiluminescence. TGF- expression was ana- (P  0.01, 99% CI, 64 to 92 days). Irrespective of the
lyzed densitometrically using a gel-pro-analyzer software treatment regime COL4A3 / mice could not be dis-
(Media Cybernetics, Silver Springs, MI, USA). Each tinguished from healthy control animals until uremic
symptoms developed a few days before death.Western blot was repeated three times.
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Fig. 3. Serum urea levels were measured every other week. Elevation
Fig. 2. Proteinuria was measured by urine protein microelectrophore- of urea above the normal range (50 mg/dL) was postponed by early
sis every other week. Compared to untreated COL4A3 /mice, early short and early long therapy by 3 weeks (7.5 vs. 10.5 weeks, P  0.01).
therapy delayed onset of proteinuria by 2 weeks and reduced its increase Late therapy did not delay the elevation of urea. N is the number of
and its maximal amount by 80% in week 9. When ramipril therapy animals represented of each group; *P  0.05 (compared to healthy
was continued after the 10th week of life, no additional beneficial controls). Symbols are: () wild placebo/ramipril, N  8; () homozy-
effect on reducing the amount of proteinuria was found. However, gous late therapy, N 5; () homozygous placebo, N 6; () homozy-
discontinuation of medication in the early short therapy group lead to gous early short-therapy, N  5; () homozygous early long-therapy,
a slight increase of proteinuria. Late therapy reduced proteinuria from N  5.
about 6 g/L in week 7 to 3.5 g/L in week 9. N is the number of animals
represented of each group; *P  0.05 (compared to healthy controls).
Symbols are: () wild placebo/ramipril, N  8; () homozygous late
therapy, N  5; () homozygous placebo, N  6; () homozygous
Late therapy with ramipril, starting at week 7 (group II),early short-therapy, N  5; () homozygous early long-therapy, N 5.
significantly reduced urea levels to 169  19 mg/dL in
week 9 (P  0.05), while the early therapy (group III
and IV) delayed any elevation of urea by 3 weeks to
Proteinuria and uremia were delayed in week 10. The early therapy also slowed down the speed
COL4A3 / mice by ramipril therapy of deterioration of renal function, as shown by the urea
Untreated COL4A3 / mice developed proteinuria levels at week 12 (early short therapy 102  30 mg/dL,
at about 6 weeks of age, proceeding to typical nephrotic early long therapy 78  19 mg/dL; P  0.01; Fig. 3).
syndrome by week 8, with edema, hypercholesterolemia
Glomerular basement membrane changes occurred in(131  15 vs. 97  12 mmol/L in wild-type controls; P 
COL4A3 / mice despite therapy0.01, data not shown). By this age, the proteinuria had
reached 5 g/L (Fig. 2) and increased even higher to Typical for AS is the characteristic thickening and
10 g/L prior death from ESRF. splitting of the glomerular basement membrane (GBM).
Ramipril reduced the level of proteinuria and slowed Electron microscopy of COL4A3 / mice showed
down its increase in all groups. Group II (late therapy), these changes to be present irrespective of the therapy
while having no effect upon lifespan, did reduce protein- regime (Fig. 4 e, i) with no obvious modification in the
uria from about 6 g/day in week 7 to about 3.5 g/day at pathological structure of the GBM between either the
week 9. Untreated COL4A3 / mice showed massive treated or untreated COL4A3 / animals. However,
proteinuria of about 12 g/day at week 9. Early therapy abnormal intracellular amounts of fibrillar collagens and
(group III and IV) delayed onset of proteinuria by two a complete loss of the podocyte foot-processes in un-
weeks and reduced its severity. There were no significant treated animals could be observed at a lower magnifica-
differences in the reduction of proteinuria in the early tion (Fig. 4f). These changes appeared to be improved
versus the late therapy group in weeks 10 and 11. A by early ramipril therapy as foot-processes and the slit-
slight increase of proteinuria was noted in week 11 in membrane could still be found at week 7 (Fig. 4 i, j).
the early short-therapy group (group III) one week after
Ramipril reduced abnormal deposition of the renaldiscontinuation of ramipril.
extracellular matrix in COL4A3 / mice leadingIn untreated mice serum urea started to rise above
to fibrosis and renal failure50 mg/dL in week 7, indicating deterioration of renal
function (Fig. 3). Mice became uremic (urea 247  27 Light microscopy (Fig. 4) showed periglomerular and
interstitial fibrosis in untreated animals (Fig. 4g) withmg/dL in week 9), ate and drunk less and died soon after.
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Fig. 4. Representative photomicrographs from wild-type controls (a–d), untreated COL4A3 / (e–h), and early treated COL4A3 / mice (i–l).
Electron microscopy: healthy controls show a typical trilaminar structure of the glomerular basement membrane (GBM), consisting of two laminae
rarae and one lamina densa (all mice 7 weeks of age). Normal podocyte foot-processes are noted with the split-membrane in between (a, b). In
contrast, both treated (i) and untreated (e) COL4A3 / mice show characteristic thickening and splitting of the GBM (magnification: 15,000- to
20,000-fold). Lower magnification (5000- to 7000-fold) demonstrates a complete loss of the podocyte foot-processes, a marked hypercellularity
and intracellular masses of fibrillar collagens (f). These changes appear to be slightly improved by early therapy in week 7 ( j), as some foot-
processes with a normal looking split membrane are seen (i). Light microscopy: 500 nm kidney sections of untreated animals (g) show periglomerular
and tubulointerstitial fibrosis in week 7, leading to general fibrosis and glomerulosclerosis, that cause end stage renal failure in week 10 (h). In
the treated group IV, less fibrotic changes are noted in week 7 (k). Delayed fibrosis leads to a preserved architecture of the glomerulus in week
10 (l) (healthy controls: c, d; magnification: 600- to 800-fold).
marked glomerular hypercellularity and thickening of plete loss of glomerular function and nephrons, leading
to ESRF in week 10 (Fig. 4h).the Bowman’s capsule. Tubular cells contained numer-
ous intracellular vesicles, due to reabsorption of urinary Fibrotic changes were far less severe in the early ther-
apy group in week 7 (Fig. 4k) and the differences be-proteins, which occurs in severe proteinuria. Changes
proceeded to glomerulosclerosis and fibrosis with a com- tween untreated (Fig. 4h) and treated (Fig. 4l) animals
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Fig. 5. Representative figures from wild-type controls (a and d), untreated COL4A3 / mice (b and e) and treated COL4A3 / mice (c and
f ). Immunohistochemistry shows that all 3 glomeruli stained for fibronectin have severe glomerulosclerosis in untreated mice (b; healthy control,
a). This is much less apparent in the 3 glomeruli of treated animals (c). Deposition of extracellular matrix is demonstrated by staining for laminin
1 in d, e and f in an overview and a high magnification of one glomerulus. The overview allows an objective, representative impression on renal
damage and fibrosis. Compared to healthy controls (d), untreated animals (e) show a severely increased deposition of extracellular matrix in week
10. This deposition of extracellular matrix is markedly decreased in the treated group (f). In correspondence to the thick and split GBM in both
treated and untreated animals in electron microscopy, high magnification of one glomerulus in the treated group (f) shows an abnormally thick
and split basement membrane (healthy control, d).
were even more striking by week 10, with ramipril treat- onstrated also by staining with a polyclonal antibody
reacting with the three subunits in laminin 1 (laminins 1,ment leading to glomerular architecture and marked less
fibrosis. 1, 1). Healthy controls showed a thin tubular and
glomerular basement membrane (Fig. 5d) with no inter-Immunohistochemistry confirmed changes in the ex-
tracellular matrix (Fig. 5): While wild-type mice showed tubular deposition of laminin when viewed at a high
magnification. In contrast, untreated animals showed ascant staining for fibronectin (Fig. 5a), this was markedly
increased in the periglomerular matrix of untreated severely increased deposition of extracellular matrix
(Fig. 5e), laminin staining being present in the intraglom-COL4A3 / mice, a typical finding seen in severe glo-
merulosclerosis (Fig. 5b). The staining for fibronectin erular and periglomerular as well as in the intertubular
regions. Localized shrinkage of tubular lumen was noted,was much reduced in treated animals being only slightly
stronger than in healthy controls (Fig. 5 a, c). indicating loss of function of different nephrons. Early
treatment with ramipril resulted in an increased signalIncreased deposition of extracellular matrix was dem-
Gross et al: Medical therapy in Alport syndrome444
of the GBM of COL4A3 / mice (Fig. 5f) when com-
pared to healthy controls (Fig. 5d), probably due to the
ultrastructural changes documented earlier (electron mi-
croscopy in Fig. 4i). However, compared to untreated
COL4A3/mice, the periglomerular and intertubular
signal was markedly decreased with an almost normal
staining in the intertubular space and a preserved tubular
lumen, suggesting a preserved function of nephrons in
treated mice. For statistical analysis, glomeruli of three
different animals of each group were evaluated for glo-
merulosclerosis in week 10 by a blinded observer [11].
Glomerulosclerosis was defined as a loss of more than 50%
of glomerular lumen due to extracellular matrix accumula-
tion. Two out of 88 (2.3%) glomeruli of healthy controls
Fig. 6. Western blot for TGF-1 (25 kD) in treated and untreatedshowed sclerosis, whereas 81 out of 92 (88.0%) did in
Alport-mice. Compared to untreated COL4A3 / mice (lanes 5 and
untreated COL4A3 / animals. In contrast, only 15 6), early ramipril therapy (lanes 3 and 4) causes a 7- to 12-fold down-
regulation of TGF-1. This effect is much less apparent in the lateout of 90 (16.7%) of glomeruli of treated COL4A3 /
therapy group (lane 1, down-regulation by 50%). Compared to earlymice showed sclerosis. Tubulointerstitial fibrosis was
long-therapy group in week 12 (lane 7), levels of TGF-1 in the early
evaluated in a similar matter by grading 12 different short-therapy group again start to rise by 20% two weeks after discontin-
uation of therapy, suggesting that TGF-may be involved in the fibrotickidney sections of three different animals per experimen-
process. IOD stands for integrated optical density. N is the number oftal group (total of 36 sections) into zero, 1
 and 2

animals pooled.
accumulation of extracellular matrix [12]. Healthy con-
trols showed no accumulation of extracellular matrix in
any section. Untreated COL4A3 / mice showed an
maintained under specific pathogen-free housing condi-average matrix score of 1.83, whereas the early treatment
tions reduced the likelihood of intercurrent infectionsgroup showed an average matrix score of 0.69.
altering the course of the disease.
Early ramipril therapy led to reduced TGF-1 In humans with AS, similar studies to evaluate the
expression in COL4A3 / mice benefit of any medical therapy on renal failure seem to
be impossible. Due to small family numbers, the variabil-We speculated that the nephroprotective effect of ram-
ity in the genetic mutations in the COL4A genes, andipril in the COL4A3/mice operates by down-regula-
the long course of disease where one has to wait 20tion of TGF-, which results in a reduction in fibrosis.
to 30 years to evaluate the benefit of any therapeuticTotal protein was extracted and 30	g aliquots (as shown
intervention, there are no reliable clinical data available.by the BCA protein assay; Pierce, Munich, Germany)
The COL4A3 knockout mouse is the only non-hyper-were separated by polyacrylamide gel electrophoresis
tensive, non-inflammatory animal model of chronic pro-(PAGE), and immunoblotted with an antibody against
gressive renal disease. A nephroprotective and antifibroticTGF-1. Figure 6 shows the TGF-1 signal in pooled
effect of ramipril was clearly demonstrated. Lifespankidneys of treated versus untreated COL4A3 / mice:
until death from uremia—the clearest and most impor-Compared to untreated COL4A3/mice (lanes 5 and
tant end point—was prolonged by more than 100% in6), early ramipril-therapy (lanes 3 and 4) caused a strong
early long therapy.down-regulation of TGF-1. This effect was much re-
Early starting life-long therapy had the greatest effectduced in the late therapy group (lane 1). Compared to
on lifespan, but the reason for this is open to conjecture.early long-therapy group in week 12 (lane 7), levels of
One major effect of ACE-inhibitors such as ramipril isTGF-1 in the early short-therapy group started to rise
their ability to lower blood pressure. However, a reduc-two weeks after discontinuation of treatment.
tion in blood pressure has never been shown to have a
beneficial effect for humans suffering from AS and, in-
DISCUSSION deed, during the first 10 to 15 years, hypertension does
The COL4A3 / mouse has been shown to be a not appear to play a major part in the pathogenesis of
suitable animal model of human AS. All untreated ani- the renal failure [13]. Similarly in this mouse model there
mals showed a similar temporal onset of uremia and pro- were no signs of severe hypertension. Several other points
teinuria resulting in death between 10 and 11 weeks of in our study indicate, that the antihypertensive effect of
age. These reproducible changes are due to the common ramipril does not play a major part in prevention of renal
null mutation of the 3 (IV) chain as well as the identical failure: In the late therapy group of COL4A3 / mice
from week 7, when one might have expected signs of129 genetic background. Furthermore, the use of animals
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renal hypertension to develop, there was no improve- Ramipril did not improve the structural damage of
the GBM caused by the loss of the 3(IV), 4(IV) andment in lifespan in any statistical significant manner.
Further animals stopping treatment at week 10 had a 5(IV) chain and persistence of the 1/2(IV) chain.
Previous studies showed some evidence that abnormalmarkedly improved lifespan, though one would have
expected severe hypertension upon withdrawal of the composition of the GBM leads to secondary events re-
sulting in renal fibrosis [19, 20]. The antifibrotic andantihypertensive leading to a rapid deterioration in renal
function. These results are in agreement with the findings nephroprotective effects of ramipril influence some of
those secondary events and delay glomerular, periglom-that ACE-inhibitors have nephroprotective effects inde-
pendent of lowering systemic blood pressure, for in- erular and tubulointerstitial fibrosis (Fig. 5).
Cyclosporine A is the only drug previously shown tostance, in dogs with X-linked hereditary nephritis [14],
and have antiproteinuric effects in children with AS [15]. reduce proteinuria in children with AS [21, 22]. However,
any beneficial effects on preserving renal function haveUrinary proteins have been shown to induce progres-
sive interstitial fibrosis [16] and the known antiprotein- not yet been demonstrated. In addition, treating children
with Alport syndrome with this immunosuppressive anduric effects of ACE-inhibitors have been suggested to
be nephroprotective. In our current study, a strong anti- potentially nephrotoxic drug has many drawbacks, hin-
dering us to use cyclosporine A in any of our 400 Alportproteinuric effect of ramipril could be demonstrated in
all treated mice. This antiproteinuric action, however, families. To our knowledge for the first time, an alterna-
tive to cyclosporine A with much less dangerous sideshowed no beneficial effects on lifespan in the late ther-
apy group, but doubled the lifespan in the early therapy effects and one proven to have nephroprotective and anti-
fibrotic effects leading to a delay in renal failure has beengroup IV. The late therapy group has been exposed to
proteinuria in weeks 6 and 7 before ramipril treatment analyzed in an adequate animal model for human AS.
The normal lifespan of wild-type control mice was 565started. It can be speculated that this ongoing proteinuria
triggered or caused progressive renal fibrosis, which days and the lifespan in untreated COL4A3 / mice
was 71 days (13% of normal life expectancy). The life-could not be delayed further or reduced by ACE-inhibi-
tion. Therefore, the antiproteinuric action of ramipril span in treated mice was improved to 150 days (27%).
Large rearrangements in the COL4A3 gene in humansmay well have contributed to renoprotection in this
model as it does in any other progressive models; how- leads to a juvenile type of AS and the mean age at ESRD
is at 15 years of age (17% of normal life expectancyever, there must be additional nephroprotective effects.
Ramipril showed those additional effects in preserving in humans) [8, 13]. Therefore, preemptive ramipril ther-
apy in humans with AS is estimated to delay renal failurerenal function in other human renal diseases [17]. ACE-
inhibitors are known to be involved in the bradykinin by more than 15 years. Ramipril did not improve renal
outcome in our mouse model once fibrosis and deteriora-metabolism and to block conversion of angiotensin I
(Ang I) to Ang II, a renal growth factor that activates tion of renal function developed, suggesting the impor-
tance of early molecular-genetic diagnosis. As ramipril’sfibroblasts and leads to an increased synthesis of extracel-
lular matrix proteins [18]. Ang II also has been shown beneficial effect was strongly enhanced by initiation of
therapy early during pre-symptomatic disease, preemp-to be profibrotic, behaving as a cytokine, activating
mononuclear cells and increasing proinflammatory medi- tive treatment before onset of proteinuria would appear
to be crucial in humans with AS.ators [18] as well as regulating matrix degradation. Some
of these effects are mediated via the TGF- pathway,
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